New collaboration covers non-invasive cytology and AI risk-stratification to dentists across Michigan, Ohio, Indiana, and North Carolina Durham, NC — January 15th, 2026 — Delta Dental Plan of Michigan, Inc. Delta Dental Plan of Ohio, Inc., Delta Dental Plan of Indiana, Inc., (collectively “DDMI”) and Delta Dental of North Carolina(“DDNC”)[1] have reaffirmed their commitment to […]
NEW YORK, Oct. 6, 2025 — OraLiva, Inc., an AI precision diagnostics company, today announced the close of a $2.0 million oversubscribed Seed financing round. The round was led by angel Dr. Preetpal Sidhu, with participation from DCVC, RTP Angel Fund, and the NYU Innovation Venture Fund. The equity financing complements $3.5 million in non-dilutive […]
OraLiva, Inc. is preparing to launch its first noninvasive, AI-powered oral cancer test following recent NIH funding support. The test combines microfluidics, cytology, and advanced image analysis to detect mild-to-severe dysplasia earlier and more accurately than visual exams alone.
The platform is also being developed into a cartridge-based, point-of-care device that can be used directly in dental and ENT offices, with an FDA submission planned in the coming years
OraLiva, Inc. is on the cusp of launching an AI-powered cytology “lab-in-a-kit” platform aimed at transforming early oral cancer diagnosis. The system captures cells via a non-invasive brush biopsy, runs them through OraLiva’s proprietary AI engine and compares the sample against a deep clinical dataset to detect early dysplasia or malignancy with high precision.
